IHH Healthcare inks deal with Perennial for ParkwayHealth Chengdu Hospital
MAINBOARD-LISTED IHH Healthcare Berhad on Friday sealed the deal with Perennial Real Estate Holdings Ltd to lease a space in Perennial International Health and Medical Hub for its 350-bed ParkwayHealth Chengdu Hospital.
Located in China, the multi-disciplinary hospital will be Chengdu's first foreign tertiary hospital.
It is also IHH's first hospital in Western China, run by its largest operating subsidiary Parkway Pantai.
Slated to open in the second half of 2017, ParkwayHealth Chengdu Hospital will be equipped with advanced medical facilities and equipment, providing specialised care and clinical services including obstetrics and gynaecology, paediatrics, cardiology, orthopaedics, ophthalmology and internal medicine.
Upon completion, the hospital is expected to serve 148 million residents in the region, and reinforce IHH's expansion into Greater China.
Tan See Leng, managing director and CEO of IHH and group CEO and managing director of Parkway Pantai, said: "Along with Gleneagles Hong Kong Hospital, ParkwayHealth Chengdu Hospital will further our plans of becoming a leading international healthcare provider in Greater China."
IHH first announced last October that it would lease at least 48,000 square metres in net leasable area from Perennial to operate ParkwayHealth Chengdu Hospital.
IHH is a major foreign-owned private healthcare operator in China, with a network of 10 medical centres in Shanghai, Beijing, Suzhou and Hong Kong. Its 500-bed Gleneagles Hong Kong Hospital is on track to open in early-2017.
IHH operates a global network of 49 hospitals across nine countries with close to 10,000 licensed beds, providing the full spectrum of integrated healthcare services.
BT is now on Telegram!
For daily updates on weekdays and specially selected content for the weekend. Subscribe to t.me/BizTimes
Companies & Markets
China’s Zeekr prices US IPO at top of range to raise US$441 million
Hin Leong founder OK Lim found guilty of 3 criminal charges
New weight-loss, diabetes drugs reach one in eight Americans
Cutting the cord?: Events leading up to Cordlife’s MOH suspension and arrests of its directors, ex-group CEO
Manulife profit beats on growth in Asia, wealth management
Sanofi inks US$1.2 billion vaccine licensing deal with Novavax